Clinical Trial Update: A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. [Phase 1]

View source ↗

Summary

A Phase I/Ib trial of NZV930 alone and in combination with PDR001 and/or NIR178 in patients with advanced malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma
• Renal Cell Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• NIR178
• NZV930
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) | Phase 1 | Status: TERMINATED